In This Article:
Theralase Technologies (CVE:TLT) Full Year 2024 Results
Key Financial Results
-
Revenue: CA$1.03m (down 3.4% from FY 2023).
-
Net loss: CA$4.26m (loss narrowed by 6.9% from FY 2023).
-
CA$0.018 loss per share (improved from CA$0.021 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Theralase Technologies Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 34%. Earnings per share (EPS) also surpassed analyst estimates by 10%.
The primary driver behind last 12 months revenue was the Canada segment contributing a total revenue of CA$896.1k (87% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to CA$2.75m (57% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CA$32.2k. Explore how TLT's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in North America.
Performance of the market in Canada.
The company's shares are down 21% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Theralase Technologies you should be aware of, and 1 of them can't be ignored.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.